📣 VC round data is live. Check it out!

Biote Valuation Multiples

Discover revenue and EBITDA valuation multiples for Biote and similar public comparables like DocGo, Radius Residential, P3 Health Partners, Third Age Health Services and more.

Biote Overview

About Biote

Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company derives revenue from United States and also has its presence in other countries.


Founded

2012

HQ

United States

Employees

217

Website

biote.com

Financials (LTM)

Revenue: $192M
EBITDA: $47M

EV

$164M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Biote Financials

Biote reported last 12-month revenue of $192M and EBITDA of $47M.

In the same LTM period, Biote generated $136M in gross profit, $47M in EBITDA, and $21M in net income.

Revenue (LTM)


Biote P&L

In the most recent fiscal year, Biote reported revenue of $192M and EBITDA of $53M.

Biote is profitable as of last fiscal year, with gross margin of 71%, EBITDA margin of 28%, and net margin of 14%.

See analyst estimates for Biote
LTMLast FY202320242025202620272028
Revenue$192M$192M$185M$197M$192M
Gross Profit$136M$137M$127M$139M$137M
Gross Margin71%71%69%71%71%
EBITDA$47M$53M$9M$16M$52M
EBITDA Margin25%28%5%8%27%
EBIT Margin16%19%15%16%18%
Net Profit$21M$27M$3M$3M$27M
Net Margin11%14%2%2%14%
Net Debt—$83M———

Financial data powered by Morningstar, Inc.

Biote Stock Performance

Biote has current market cap of $61M, and enterprise value of $164M.

Market Cap Evolution


Biote's stock price is $1.99.

Biote share price decreased by 10.1% in the last 30 days, and by 42.3% in the last year.

Biote has an EPS (earnings per share) of $0.89.

See more trading valuation data for Biote
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$164M$61M0.0%-10.1%-5.9%-42.3%$0.89

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Biote Valuation Multiples

Biote trades at 0.9x EV/Revenue multiple, and 3.5x EV/EBITDA.

See NTM and 2027E valuation multiples for Biote

EV / Revenue (LTM)


Biote Financial Valuation Multiples

As of May 26, 2026, Biote has market cap of $61M and EV of $164M.

Biote has a P/E ratio of 2.9x.

LTMLast FY202320242025202620272028
EV/Revenue0.9x0.9x0.9x0.8x0.9x
EV/EBITDA3.5x3.1x17.7x10.5x3.1x
EV/EBIT5.2x4.5x5.7x5.2x4.6x
EV/Gross Profit1.2x1.2x1.3x1.2x1.2x
P/E2.9x2.2x18.2x19.2x2.2x
EV/FCF7.6x5.8x6.8x4.3x5.8x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Biote Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Biote Margins & Growth Rates

Biote decreased revenue by 1% and EBITDA by 28% in the last fiscal year.

In the most recent fiscal year, Biote reported gross margin of 71%, EBITDA margin of 28%, and net margin of 14%.

See estimated margins and future growth rates for Biote

Biote Margins

Last FY202420252026202720282029
Gross Margin71%71%71%70%
EBITDA Margin28%8%27%20%
EBIT Margin19%16%18%12%
Net Margin14%2%14%6%
FCF Margin15%19%15%7%

Biote Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth(1%)6%(3%)(1%)
Gross Profit Growth(3%)9%(1%)(3%)
EBITDA Growth(28%)69%235%(27%)
EBIT Growth(37%)10%12%(35%)
Net Profit Growth(57%)(5%)757%(57%)
FCF Growth(56%)58%(26%)(56%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Biote Operational KPIs

Biote's revenue per employee in the last FY averaged $0.9M, while opex per employee averaged $0.5M for the same period.

Biote's Rule of 40 is 19% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Biote's Rule of X is 18% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Biote
LTMLast FY202320242025202620272028
Rule of 4027%19%———
Bessemer Rule of X30%18%———
Revenue per Employee—$0.9M———
Opex per Employee—$0.5M———
S&M Expenses to Revenue0%0%——0%
Opex to Revenue—53%53%54%53%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
DocGo0.2x0.2x(1.9x)(2.6x)
Radius Residential1.8x1.5x10.4x8.7x
P3 Health Partners0.2x0.2x(2.3x)(4.4x)
Third Age Health Services2.6x—11.1x—
Maternus-Kliniken1.7x—18.6x—
Joint2.0x1.9x8.4x8.7x
Eureka Group Holdings7.9x7.2x10.8x18.0x
Oceania Healthcare4.4x3.3x16.8x16.6x

This data is available for Pro users. Sign up to see all Biote competitors and their valuation data.

Start Free Trial

Biote M&A Activity

Biote has acquired 1 company to date.

Last acquisition by Biote was on January 17th 2024. Biote acquired Asteria Health for $9M (EV/Revenue multiple of ).

See M&A valuation multiples

Latest Acquisitions by Biote

Asteria Health
Description
Asteria Health is a US-based producer of sterile compounding kits and IV bags for outpatient clinics and hospitals. Certified under CGMP standards, its products include pre-filled syringes for pain management and chemotherapy. Established in 2018, the company distributes to 1,000 facilities nationwide from ISO 7 cleanrooms in Florida.
HQ CountryUnited Kingdom
HQ City
Birmingham
Deal Date17 Jan 2024
Valuation$9M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Biote acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Biote

When was Biote founded?Biote was founded in 2012.
Where is Biote headquartered?Biote is headquartered in United States.
How many employees does Biote have?As of today, Biote has over 217 employees.
Is Biote publicly listed?Yes, Biote is a public company listed on Nasdaq.
What is the stock symbol of Biote?Biote trades under BTMD ticker.
When did Biote go public?Biote went public in 2022.
Who are competitors of Biote?Biote main competitors include DocGo, Radius Residential, P3 Health Partners, Third Age Health Services, Maternus-Kliniken, Joint, Eureka Group Holdings, Oceania Healthcare, Propel Funeral Partners, LNA Sante.
What is the current market cap of Biote?Biote's current market cap is $61M.
What is the current revenue of Biote?Biote's last 12 months revenue is $192M.
What is the current revenue growth of Biote?Biote revenue growth (NTM/LTM) is 2%.
What is the current EV/Revenue multiple of Biote?Current revenue multiple of Biote is 0.9x.
Is Biote profitable?Yes, Biote is EBITDA-positive (as of the last 12 months).
What is the current EBITDA of Biote?Biote's last 12 months EBITDA is $47M.
What is Biote's EBITDA margin?Biote's last 12 months EBITDA margin is 25%.
What is the current EV/EBITDA multiple of Biote?Current EBITDA multiple of Biote is 3.5x.
What is the current FCF of Biote?Biote's last 12 months FCF is $22M.
What is Biote's FCF margin?Biote's last 12 months FCF margin is 11%.
What is the current EV/FCF multiple of Biote?Current FCF multiple of Biote is 7.6x.
How many companies Biote has acquired to date?As of May 2026, Biote has acquired 1 company.
What was the largest acquisition by Biote?$9M acquisition of Asteria Health on 17th January 2024 was the largest M&A Biote has done to date.
What companies Biote acquired?Biote acquired Asteria Health.
In how many companies Biote has invested to date?Biote hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Biote

Lists including Biote

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial